Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice.

Sakakibara K, Sato T, Kufe DW, VonHoff DD, Kawabe T.

Oncotarget. 2017 Sep 16;8(45):78277-78288. doi: 10.18632/oncotarget.20968. eCollection 2017 Oct 3.

2.

CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding.

Saito N, Mine N, Kufe DW, Von Hoff DD, Kawabe T.

Oncotarget. 2017 Jun 22;8(43):74006-74018. doi: 10.18632/oncotarget.18598. eCollection 2017 Sep 26.

3.

CBP501 suppresses macrophage induced cancer stem cell like features and metastases.

Mine N, Yamamoto S, Saito N, Sato T, Sakakibara K, Kufe DW, VonHoff DD, Kawabe T.

Oncotarget. 2017 Jul 17;8(38):64015-64031. doi: 10.18632/oncotarget.19292. eCollection 2017 Sep 8.

4.

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, Yuan GC, Kufe DW, Jänne PA, Hammerman PS, Sholl LM, Hodi FS, Richards WG, Bueno R, English JM, Bittinger MA, Wong KK.

JCI Insight. 2016 Sep 8;1(14):e89014.

5.

CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.

Saito N, Sakakibara K, Sato T, Friedman JM, Kufe DW, VonHoff DD, Kawabe T.

Mol Cancer Ther. 2014 Dec;13(12):3013-23. doi: 10.1158/1535-7163.MCT-14-0064. Epub 2014 Sep 24.

6.

Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.

Mine N, Yamamoto S, Kufe DW, Von Hoff DD, Kawabe T.

Mol Cancer Ther. 2014 Sep;13(9):2215-25. doi: 10.1158/1535-7163.MCT-13-0808. Epub 2014 Jul 22.

7.

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.

Kufe DW.

Oncogene. 2013 Feb 28;32(9):1073-81. doi: 10.1038/onc.2012.158. Epub 2012 May 14. Review.

8.

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.

Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T.

Blood. 2011 Oct 6;118(14):3922-31. doi: 10.1182/blood-2011-01-333138. Epub 2011 Aug 12.

9.

CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.

Mine N, Yamamoto S, Saito N, Yamazaki S, Suda C, Ishigaki M, Kufe DW, Von Hoff DD, Kawabe T.

Mol Cancer Ther. 2011 Oct;10(10):1929-38. doi: 10.1158/1535-7163.MCT-10-1139. Epub 2011 Aug 10.

10.

Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.

Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff D, Kawabe T, Sharma S.

Clin Cancer Res. 2011 May 15;17(10):3431-42. doi: 10.1158/1078-0432.CCR-10-2345. Epub 2011 Jan 10.

11.

MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients.

MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW, Weichselbaum RR.

BMC Med Genomics. 2010 May 6;3:16. doi: 10.1186/1755-8794-3-16.

12.

Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells.

Meng Y, Mauceri HJ, Khodarev NN, Darga TE, Pitroda SP, Beckett MA, Kufe DW, Weichselbaum RR.

Mol Ther. 2010 May;18(5):912-20. doi: 10.1038/mt.2010.18. Epub 2010 Mar 2.

13.

Mucins in cancer: function, prognosis and therapy.

Kufe DW.

Nat Rev Cancer. 2009 Dec;9(12):874-85. doi: 10.1038/nrc2761. Review.

14.

Functional targeting of the MUC1 oncogene in human cancers.

Kufe DW.

Cancer Biol Ther. 2009 Jul;8(13):1197-203. Epub 2009 Jul 27. Review. No abstract available.

15.

MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer.

Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR.

Cancer Res. 2009 Apr 1;69(7):2833-7. doi: 10.1158/0008-5472.CAN-08-4513. Epub 2009 Mar 24.

16.

MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.

Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5837-41. doi: 10.1073/pnas.0812029106. Epub 2009 Mar 16.

17.

Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

Mauceri HJ, Beckett MA, Liang H, Sutton HG, Pitroda S, Galka E, Efimova E, Darga T, Khodarev NN, King CR, Posner MC, Hellman S, Kufe DW, Weichselbaum RR.

Cancer Gene Ther. 2009 Apr;16(4):373-81. doi: 10.1038/cgt.2008.86. Epub 2008 Oct 31.

18.

Targeting the human MUC1 oncoprotein: a tale of two proteins.

Kufe DW.

Cancer Biol Ther. 2008 Jan;7(1):81-4. Epub 2008 Feb 11. No abstract available.

PMID:
18347419
19.

Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB.

Katdare M, Efimova EV, Labay E, Khodarev NN, Darga TE, Garofalo M, Nakamura S, Kufe DW, Posner MC, Weichselbaum RR.

Int J Oncol. 2007 Dec;31(6):1519-28.

PMID:
17982679
20.

Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding.

Yamini B, Yu X, Dolan ME, Wu MH, Darga TE, Kufe DW, Weichselbaum RR.

Cancer Res. 2007 Jul 15;67(14):6889-98. Erratum in: Cancer Res. 2009 Feb 15;69(4):1695. Darga, Thomas E [added].

21.

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.

Sha SK, Sato T, Kobayashi H, Ishigaki M, Yamamoto S, Sato H, Takada A, Nakajyo S, Mochizuki Y, Friedman JM, Cheng FC, Okura T, Kimura R, Kufe DW, Vonhoff DD, Kawabe T.

Mol Cancer Ther. 2007 Jan;6(1):147-53.

22.

Chemo-inducible gene therapy.

Mezhir JJ, Schmidt H, Yamini B, Senzer NN, Posner MC, Kufe DW, Weichselbaum RR.

Anticancer Drugs. 2005 Nov;16(10):1053-8. Review.

PMID:
16222146
23.

Ionizing radiation: a genetic switch for cancer therapy.

Mezhir JJ, Smith KD, Posner MC, Senzer N, Yamini B, Kufe DW, Weichselbaum RR.

Cancer Gene Ther. 2006 Jan 1;13(1):1-6. Review.

PMID:
16082378
24.

Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma.

Murphy KT, Wardak A, Beckett MA, Lopez CA, Mehta N, Kimchi E, Salloum RM, Jaskowiak NT, Posner MC, Ohno T, Kufe DW, Weichselbaum RR, Mauceri HJ.

Cancer Chemother Pharmacol. 2005 Sep;56(3):317-21. Epub 2005 May 11.

PMID:
15887016
25.

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T.

J Immunother. 2004 Nov-Dec;27(6):452-9.

PMID:
15534489
26.

Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.

Yamini B, Yu X, Gillespie GY, Kufe DW, Weichselbaum RR.

Cancer Res. 2004 Sep 15;64(18):6381-4.

27.

Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity.

Lopez CA, Kimchi ET, Mauceri HJ, Park JO, Mehta N, Murphy KT, Beckett MA, Hellman S, Posner MC, Kufe DW, Weichselbaum RR.

Mol Cancer Ther. 2004 Sep;3(9):1167-75.

28.

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.

Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR.

Clin Cancer Res. 2004 Sep 1;10(17):5747-53.

29.

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.

Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.

Br J Haematol. 2004 May;125(3):343-52.

PMID:
15086415
30.

Antitumor effects of fusions composed of dendritic cells and fibroblasts transfected with genomic DNA from tumor cells.

Nakamura M, Kikuchi T, Kufe DW, Ohno T.

Cancer Immunol Immunother. 2004 Aug;53(8):690-6. Epub 2004 Mar 16.

PMID:
15024501
31.
32.

Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model.

Gupta VK, Park JO, Kurihara T, Koons A, Mauceri HJ, Jaskowiak NT, Kufe DW, Weichselbaum RR, Posner MC.

Gene Ther. 2003 Feb;10(3):206-12.

PMID:
12571627
33.

Angiostatin potentiates cyclophosphamide treatment of metastatic disease.

Mauceri HJ, Seetharam S, Beckett MA, Schumm LP, Koons A, Gupta VK, Park JO, Manan A, Lee JY, Montag AG, Kufe DW, Weichselbaum RR.

Cancer Chemother Pharmacol. 2002 Nov;50(5):412-8. Epub 2002 Sep 18.

PMID:
12439600
34.

Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy.

Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, Mauceri HJ.

Lancet Oncol. 2002 Nov;3(11):665-71. Review.

PMID:
12424068
35.

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW.

J Clin Oncol. 2002 Sep 15;20(18):3772-84.

PMID:
12228197
36.

Transcriptional control of viral gene therapy by cisplatin.

Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE, Manan A, Hellman S, Posner MC, Kufe DW, Weichselbaum RR.

J Clin Invest. 2002 Aug;110(3):403-10.

37.

Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane.

Epperly MW, Sikora CA, DeFilippi SJ, Gretton JA, Zhan Q, Kufe DW, Greenberger JS.

Radiat Res. 2002 May;157(5):568-77.

PMID:
11966323
38.

Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance.

Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, Calvin DA, Nodzenski E, Pejovic M, Kufe DW, Posner MC, Weichselbaum RR.

Cancer J. 2002 Jan-Feb;8(1):47-54.

PMID:
11895203
39.

Tumor production of angiostatin is enhanced after exposure to TNF-alpha.

Mauceri HJ, Seetharam S, Beckett MA, Lee JY, Gupta VK, Gately S, Stack MS, Brown CK, Swedberg K, Kufe DW, Weichselbaum RR.

Int J Cancer. 2002 Feb 1;97(4):410-5.

40.

Molecular targeting of gene therapy and radiotherapy.

Weichselbaum RR, Kufe DW, Advani SJ, Roizman B.

Acta Oncol. 2001;40(6):735-8. Review.

PMID:
11765068
41.

Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.

Bunnell CA, Supko JG, Eder JP Jr, Clark JW, Lynch TJ, Kufe DW, Shulman LN.

Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55.

PMID:
11761451
42.

Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation.

Chmura SJ, Gupta N, Advani SJ, Kufe DW, Weichselbaum RR.

Semin Radiat Oncol. 2001 Oct;11(4):338-45. Review.

PMID:
11677658
43.

Angiostatin effects on endothelial cells mediated by ceramide and RhoA.

Gupta N, Nodzenski E, Khodarev NN, Yu J, Khorasani L, Beckett MA, Kufe DW, Weichselbaum RR.

EMBO Rep. 2001 Jun;2(6):536-40.

44.

Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.

Akewanlop C, Watanabe M, Singh B, Walker M, Kufe DW, Hayes DF.

Cancer Res. 2001 May 15;61(10):4061-5.

45.

Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.

Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK.

J Clin Oncol. 2001 Feb 1;19(3):857-69.

PMID:
11157040
46.

NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.

Salloum RM, Jaskowiak NT, Mauceri HJ, Seetharam S, Beckett MA, Koons AM, Hari DM, Gupta VK, Reimer C, Kalluri R, Posner MC, Hellman S, Kufe DW, Weichselbaum RR.

Cancer Res. 2000 Dec 15;60(24):6958-63.

47.

Antitumor interaction of short-course endostatin and ionizing radiation.

Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR.

Cancer J. 2000 Sep-Oct;6(5):287-93.

PMID:
11079167
48.

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.

Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP Jr.

Cancer Chemother Pharmacol. 2000;46(4):319-28.

PMID:
11052630
49.

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

Kurihara T, Brough DE, Kovesdi I, Kufe DW.

J Clin Invest. 2000 Sep;106(6):763-71.

50.

Angiostatin induces mitotic cell death of proliferating endothelial cells.

Hari D, Beckett MA, Sukhatme VP, Dhanabal M, Nodzenski E, Lu H, Mauceri HJ, Kufe DW, Weichselbaum RR.

Mol Cell Biol Res Commun. 2000 May;3(5):277-82.

PMID:
10964751

Supplemental Content

Support Center